Lymphoma Clinical Trials in New York

Showing 601-620 of 620 trials

Host Dendritic Cells in Allograft Patients

NCT00935597

The purpose of this study is to assess preliminary efficacy and to determine the safety and feasibility of ex vivo generated dendritic cell (HDC) infusion with and without donor lymphocyte infusion (DLI) after allogeneic stem cell transplant (SCT). We also wish to establish the feasibility of apheresis shipment as well as vaccine shipment and stability in the population.

Relapsed Non-Hodgkin's LymphomaHodgkin's DiseaseMultiple Myeloma+1 more

Icahn School of Medicine at Mount Sinai25 participantsStarted Aug 2009

New York, New York, United States

COMPLETEDPhase 2< 1 mile

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

NCT00049439

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining lomustine, etoposide, cyclophosphamide, and procarbazine in treating patients who have AIDS-related non-Hodgkin's lymphoma.

Lymphoma

Case Comprehensive Cancer Center54 participantsStarted Mar 1998

New York, New York, United States • Cleveland, Ohio, United States • Nairobi, Kenya +1 more locations

Host Dendritic Cells in Allograft Patients

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Meaning-Centered Psychotherapy in Advanced Cancer

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in New York